Shojaei
Amir Shojaei, Baton Rouge, LA US
Patent application number | Description | Published |
---|---|---|
20140303287 | Self-Healing Composite of Thermoset Polymer and Programmed Super Contraction Fibers - A composition comprising thermoset polymer, shape memory polymer to facilitate macro scale damage closure, and a means for molecular scale healing is disclosed; the composition has the ability to resolve structural defects by a bio-mimetic close-then heal process. In use, the shape memory polymer serves to bring surfaces of a structural defect into approximation, whereafter use of the means for molecular scale healing allowed for movement of the healing means into the defect and thus obtain molecular scale healing. The means for molecular scale healing can be a thermoplastic such as fibers, particles or spheres which are used by heating to a level at or above the thermoplastic's melting point, then cooling of the composition below the melting temperature of the thermoplastic. Compositions of the invention have the ability to not only close macroscopic defects, but also to do so repeatedly even if another wound/damage occurs in a previously healed/repaired area. | 10-09-2014 |
Amir Shojaei, Phoenixville, PA US
Borzoyeh Shojaei, Folsom, CA US
Patent application number | Description | Published |
---|---|---|
20120132570 | Nanoparticle Separation Methods and Compositions - Methods of separating one type of nanoparticle from another type of nanoparticle in a mixture including more than one type of nanoparticle are disclosed. The methods may include suspending a mixture of the various types of nanoparticles in a liquid and modifying a characteristic of the liquid. Thereafter, a force may be applied to the nanoparticles within the mixture causing one type of nanoparticles to separate from another type of nanoparticles. The applied force may be the force of gravity, or it may be an induced force such as a centrifugal force applied with a centrifuge or similar apparatus. Upon the occurrence physical separation, sub-populations of nanoparticles may be removed from the suspension or segregated. Alternatively the methods may include modifying a type of nanoparticle in suspension. Alternative embodiments include nanoparticles modified in suspension to provide for separation from other types of nanoparticles. | 05-31-2012 |
Fabod Shojaei, Santa Clara, CA US
Patent application number | Description | Published |
---|---|---|
20100316633 | INHIBITION OF ANGIOGENESIS - The present invention relates generally to the inhibition of inflammatory cell-mediated angiogenesis. In particular, the invention concerns the prevention or treatment of tumor angiogenesis, and the inhibition of tumor development, using Bv8 antagonists, such as anti-Bv8 antibodies. | 12-16-2010 |
Farbod Shojaei, San Diego, CA US
Patent application number | Description | Published |
---|---|---|
20160031984 | HUMANIZED ANTIBODIES THAT BIND LGR5 - Disclosed herein are humanized anti-LGR5 antibodies for the treatment of cancer. Antibodies disclosed herein may bind LGR5 without disrupting LGR5-RSPO1 binding or signaling, and may disrupt LGR5 signaling through Wnt that is independent of RSPO1. Also disclosed are heavy and light chain polypeptide sequences for the biding of LGR5, for example without disrupting LGR5-RSPO binding or signaling. | 02-04-2016 |
Maryam Shojaei, Westmead, Nsw AU
Patent application number | Description | Published |
---|---|---|
20150322538 | RISK STRATIFICATION IN INFLUENZA - The present invention relates to methods for the identification of clinical risk in patients having, or suspected of having, influenza. The invention also relates to methods for distinguishing between patients having influenza or viral pneumonia from patients having a symptomatically similar condition. The methods of the invention comprise determination of the level of expression of interferon alpha inducible protein 27 (IF127) in a biological sample from a patient having, or suspected of having, influenza. Kits comprising suitable components for the performance of the methods are also provided by the invention. The invention allows stratification of patients into groups defining clinical risk, for example groups based on the severity of risk to the long-term health of the subject. | 11-12-2015 |